The development of therapies for central nervous system (CNS) diseases faces one of the greatest challenges in medicine: effective and safe drug delivery across the blood–brain barrier (BBB). At Prisys Biotech, we have established Asia's first intraoperative MRI (iMRI)-guided brain drug delivery system, along with complementary approaches such as intrathecal dosing, nasal-to-brain delivery, and vascular interventional technologies. These platforms provide pharmaceutical developers with precise, efficient, and translational solutions for CNS drug research.
1. iMRI-Guided Brain Drug Delivery
The iMRI-guided delivery platform represents the core of Prisys Biotech's brain-targeting technologies. By integrating MRI navigation with convection-enhanced delivery (CED), this system achieves sub-millimeter accuracy in drug administration directly to target brain structures.
Key Advantages:
- Crosses the BBB: Enables localized delivery, reducing systemic exposure.
- Real-Time Navigation: MRI visualization optimizes injection trajectory and ensures accurate targeting.
- Enhanced Distribution: CED improves drug dispersion within brain tissue.
- Translational Relevance: The same technology is used in clinical settings, bridging preclinical and human studies.
- Minimally Invasive: Microinjection procedures maximize safety and reduce trauma.
Applications:
- Gene and Cell Therapy: Supports intracranial delivery of viral vectors and cell therapies in translational CNS studies.
- Preclinical Toxicology: Enables single-dose intracerebroventricular (ICV) safety studies in cynomolgus monkeys.
- Targeted Neurological Research: Direct drug administration to specific regions such as the striatum, with bilateral precision.
Core Systems and Devices:
- ClearPoint® Navigation System and SmartFlow® Cannula for CED.
- High-field 1.5T MRI equipped with customized coils for NHP imaging.
- Advanced neuroimaging protocols (DTI, perfusion, spectroscopy, SWI) for quantitative assessment of drug distribution and disease models.
2. Additional Brain Drug Delivery Approaches
To complement iMRI-guided solutions, Prisys Biotech provides a spectrum of brain delivery technologies tailored to different therapeutic modalities:
Nasal-to-Brain (N2B) Delivery:
Non-invasive delivery route bypassing the BBB.
Supported by imaging tools (CT) to visualize deposition and brain distribution.
Suitable for evaluating formulations (dry powder or liquid sprays) in NHP models.
Lumbar puncture or cisterna magna access under ultrasound or X-ray guidance.
Enables direct CNS exposure for safety pharmacology and EEG-based functional studies.
Digital Subtraction Angiography (DSA)-Guided Delivery:
High-resolution vascular imaging to support minimally invasive catheter-based delivery.
Applied in ischemic stroke and cerebrovascular models for targeted drug infusion.
Other Targeted Routes:
Bronchoscopic administration for localized pulmonary–neurological research.
Conclusion
By integrating iMRI-guided precision injection with multiple complementary delivery routes, Prisys Biotech provides one of the most advanced brain-targeted drug delivery platforms in Asia. These technologies enable pharmaceutical partners to overcome BBB challenges, evaluate CNS-targeted therapies in translational NHP models, and accelerate the path from preclinical innovation to clinical success.
